

# Dongjoon Ko

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10022841/publications.pdf>

Version: 2024-02-01

8  
papers

136  
citations

1684188  
5  
h-index

1588992  
8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

182  
citing authors

#	ARTICLE	IF	CITATIONS
1	TMPRSS4 induces invasion and proliferation of prostate cancer cells through induction of Slug and cyclin D1. <i>Oncotarget</i> , 2016, 7, 50315-50332.	1.8	31
2	TMPRSS4 promotes cancer stemâ€like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 372.	8.6	31
3	Anti-cancer activity of the novel 2-hydroxydiarylamide derivatives IMD-0354 and KRT1853 through suppression of cancer cell invasion, proliferation, and survival mediated by TMPRSS4. <i>Scientific Reports</i> , 2019, 9, 10003.	3.3	22
4	Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity. <i>Theranostics</i> , 2017, 7, 594-613.	10.0	19
5	Cooperation between ZEB2 and Sp1 promotes cancer cell survival and angiogenesis during metastasis through induction of survivin and VEGF. <i>Oncotarget</i> , 2018, 9, 726-742.	1.8	16
6	TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 58.	8.6	8
7	Bovine Serum Albumin-Immobilized Black Phosphorus-Based $\hat{3}$ -Fe <sub>2</sub> O <sub>3</sub> Nanocomposites: A Promising Biocompatible Nanoplatform. <i>Biomedicines</i> , 2021, 9, 858.	3.2	6
8	Therapeutic effects of TM4SF5-targeting chimeric and humanized monoclonal antibodies in hepatocellular and colon cancer models. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 452-466.	4.4	3